Author

H. V. Siddle

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:proteomics· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Assay:DNA methylation· 1 Approach:experimental assay· 1 Organism:non-human primate· 1 Approach:statistical model· 1

Frequent Co-Authors

A. Bailey· 1 shared A. Bergthaler· 1 shared A. Gastaldello· 1 shared A. Lercher· 1 shared A. Orlova· 1 shared A. Popa· 1 shared A. Ringler· 1 shared A. W. Purcell· 1 shared

Activity by Year

2018-2020 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. Bailey

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Passage of transmissible cancers in the Tasmanian devil is due to a dominant, shared peptide motif and a limited repertoire of MHC-I allotypes

A. Gastaldello, S. H. Ramarathinam, A. Bailey, R. S. Owen, S. C. Turner, N. Kontouli, T. J. Elliott, P. J. S. Skipp, A. W. Purcell, H. V. Siddle

The paper identifies a shared peptide motif and limited MHC-I diversity in Tasmanian devil transmissible cancers, suggesting a mechanism for immune evasion and vaccine design.

bioRxiv · Jul 3, 2020 · PreprintImmunology

The ERBB-STAT3 Axis Drives Tasmanian Devil Facial Tumor Disease

L. Kosack, B. Wingelhofer, A. Popa, B. Vilagos, A. Orlova, P. Majek, K. Parapatics, A. Lercher, B. Agerer, A. Ringler, J. Klughammer, M. Smyth, K. Khamina, H. Baazim, D. A. Rosa, , A. Bergthaler

This study identifies the ERBB-STAT3 axis as a driver of Tasmanian devil facial tumor disease and proposes a dual chemo-immunotherapeutic strategy.

bioRxiv · Apr 12, 2018Cancer Biology